News | July 06, 2024
Nephro Care India lists at 90% premium
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Dyslipidemia is a critical risk factor for cardiovascular diseases
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The initiative aims to empower individuals to take proactive steps towards monitoring their health
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Ibara will drive AI-powered clinical research innovation
Subscribe To Our Newsletter & Stay Updated
